Patient out-of-pocket costs for biologic drugs after biosimilar competition
About The Study: The findings of this study suggest that biosimilar competition was not consistently associated with lower out-of-pocket costs for commercially insured outpatients, highlighting the need for targeted policy interventions to ensure that the savings generated from biosimilar competition translate into increased affordability for patients who need biologics.
Authors: Benjamin N. Rome, M.D., M.P.H., of Brigham and Women’s Hospital in Boston, is the corresponding author.
To access the embargoed study: ...










